Additional U.S. patent for stem cell technology.
PETACH TIKVAH, ISRAEL, April 10, 2014 -- BrainStorm Cell Therapeutics (OTCQB: BCLI) said that the U.S. Patent and Trademark Office has granted the company an additional patent for its autologous stem cell technology.
Patent No. 8,647,874 covers the production method of proprietary stem cells induced to secrete significantly elevated levels of neurotrophic factors for the treatment of neurodegenerative diseases.
The neurotrophic factors secreted by the company's patented cells include Glial Cell-Derived Neurotrophic Factor (GDNF), Brain-Derived Neurotrophic Factor (BDNF), and Vascular Endothelial Growth Factor (VEGF), known to support the neural cell network by protection of existing motor neurons, promotion of motor neuron growth, and re-establishment of nerve-muscle interaction.
In addition, the cells secrete high levels of Hepatocyte Growth Factor (HGF), which has been recently suggested to have neuroprotective effects in ALS.
|Printer friendly Cite/link Email Feedback|
|Title Annotation:||Patent News|
|Publication:||Stem Cell Business News|
|Date:||Apr 21, 2014|
|Previous Article:||SBIR grant will aid development of novel way to isolate adipose stem cells.|
|Next Article:||Joint patent on adipose stem cell platform technology.|